Novo Nordisk A/S Common Stock (NYSE: NVO)
21 Days left to seek lead plaintiff status.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements concerning Novo’s REDEFINE-1 Study. The Complaint further alleges that on December 20, 2024, Defendants disclosed information that was directly related to their prior misrepresentations and material omissions concerning Novo’s REDEFINE-1 Study and that this disclosure had the effect of correcting Defendants’ prior false and/or misleading statements which, in turn, caused Novo’s stock price to decline as investors reassessed the risks and benefits of investing in the Company.